Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Gynecologic Oncology

• Publication date

  2004-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2004.07.039PMID 15385104PMCID PMC2734270
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker.

  2003cited by this paper
• Combining Several Screening Tests: Optimality of the Risk Score

  2002cited by this paper
• Generating longitudinal screening algorithms using novel biomarkers for disease.

  2002cited by this paper
• Factors influencing serum CA125II levels in healthy postmenopausal women.

  2001cited by this paper
• Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers

  2001cited by this paper
• Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.

  2000cited by this paper
• Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.

  1999cited by this paper
• Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

  1999cited by this paper
• Screening for ovarian cancer: a pilot randomised controlled trial.

  1999cited by this paper
• Case Studies in Bayesian Statistics

  1998cited by this paper
• Changepoint Modeling of Longitudinal PSA as a Biomarker for Prostate Cancer

  1997cited by this paper
• Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers

  1995cited by this paper
• Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*)

  1995influential reference
• Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.

  1995cited by this paper
• Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR‐3) cell line

  1994cited by this paper
• Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.

  1992cited by this paper
• Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer

  1992cited by this paper
• Quantifying the potential benefit of CA 125 screening for ovarian cancer.

  1991influential reference
• An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.

  1988cited by this paper
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper
• Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer

  1986cited by this paper
• [GYNECOLOGIC ONCOLOGY].

  1963cited by this paper

• Disposable electrochemical panel immunosensing systems for the simultaneous detection of potential biomarkers of ovarian cancer

  2026cites this paper
• Mesothelin in pancreatic cancer: clinical applications and analytical considerations.

  2025cites this paper
• The Application of Circulating Tumour DNA (ctDNA) in the Diagnosis, Prognosis, and Treatment Monitoring of Gynaecological and Breast Cancers (Review)

  2025cites this paper
• Proteomic Biomarkers and Diagnostic Tools in Ovarian Cancer: Understanding Their Clinical Value and Limitations.

  2025cites this paper
• Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.

  2025cites this paper
• Deciphering the potential of proteomic-based biomarkers in women’s reproductive diseases: empowering precision medicine in gynecology

  2024cites this paper
• Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

  2024influential citation
• A Perspective Review: Analyzing Collagen Alterations in Ovarian Cancer by High-Resolution Optical Microscopy

  2024cites this paper
• Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer

  2023cites this paper
• The issues and challenges with cancer biomarkers

  2023cites this paper
• The GOG Foundation, Inc. Translational Science

  2023influential citation
• Impedimetric immunosensors for detection of biomarkers

  2022cites this paper
• Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer

  2022influential citation
• Assessing the roles of collagen fiber morphology and matrix stiffness on ovarian cancer cell migration dynamics using multiphoton fabricated orthogonal image-based models.

  2022cites this paper
• Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics

  2021cites this paper
• One-stop clinic for patients with suspected ovarian cancer: results from a retrospective outcome study of the referral pathway

  2021cites this paper
• The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer

  2021cites this paper
• Prediction of the treatment response in ovarian cancer: a ctDNA approach

  2020cites this paper
• Biomarkers in the Management of Peritoneal Metastases

  2020cites this paper
• microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges

  2020cites this paper
• Pathology of Peritoneal Metastases: The Unchartered Fields

  2020cites this paper
• Role of Collagen Fiber Morphology on Ovarian Cancer Cell Migration Using Image-Based Models of the Extracellular Matrix

  2020cites this paper
• Production of monoclonal antibody to quantify serum CA125 concentration in breast and ovarian cancer patients

  2020cites this paper
• Influence of reproductively significant autoantibodies on the quality of oocytes, obtained embryos and the chances of implantation in Assisted Reproductive Technologies cycles. Literature review

  2020cites this paper
• Patients’ subjective assessment as a decisive predictor of malignancy in pelvic masses: results of a multicentric, prospective pelvic mass study

  2020cites this paper
• One-Stop Clinic for Patients with Suspected Ovarian Cancer Pathway from a Retrospective Outcome Study

  2020cites this paper
• High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.

  2019cites this paper
• Clinical biomarkers for detection of ovarian cancer

  2019cites this paper
• TO STUDY THE ASSOCIATION OF SERUM LEVELS OF CA-125 AND IL-6 WITH EXTENT OF THE DISEASE AND POOR CLINICAL OUTCOMES

  2019cites this paper
• DEK Is a Potential Biomarker Associated with Malignant Phenotype in Gastric Cancer Tissues and Plasma

  2019cites this paper
• Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives

  2019cites this paper
• Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients

  2018cites this paper
• CA 125 DAN RISK OF MALIGNANCY INDEX (RMI)2 SEBAGAI PREDIKTOR KEGANASAN TUMOR OVARIUM TIPE EPITEL

  2018cites this paper
• 12 Potential Tumor Biomarkers for Ovarian Cancer

  2018cites this paper
• Polarization-resolved second harmonic generation imaging of human ovarian cancer

  2018cites this paper
• The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment

  2018cites this paper
• Engrailed-2 (EN2) – a novel biomarker in epithelial ovarian cancer

  2018cites this paper
• Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review

  2018cites this paper
• Change-point of multiple biomarkers in women with ovarian cancer

  2017cites this paper
• Ovarian Cancer Biomarkers in Circulation

  2017cites this paper
• Spondin2 is a new prognostic biomarker for lung adenocarcinoma

  2017cites this paper
• Malignancy Risk Index in Pelvic Mass

  2017cites this paper
• The role of biomarkers in the management of epithelial ovarian cancer

  2017cites this paper
• Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy

  2017cites this paper
• Tuulia Vallius: NOVEL PREDICTORS OF RESPONSE AND OUTCOME IN ADVANCED EPITHELIAL OVARIAN CANCER

  2017cites this paper
• Potential-resolved "in-electrode" type electrochemiluminescence immunoassay based on functionalized g-C3N4 nanosheet and Ru-NH2 for simultaneous determination of dual targets.

  2017cites this paper
• Protein biomarkers for early detection of diseases: The decisive contribution of combinatorial peptide ligand libraries.

  2017cites this paper
• The Role of Circulating Antigen and Autoantibody in Diagnosing Ovarian Cancer

  2017cites this paper
• A Review on Biomarkers accessible for the life threatening Ovarian Cancer

  2016cites this paper
• IMMUNOHISTOCHEMICAL ANALYSIS OF MESOTHELIN IN EPITHELIAL TUMOURS OF OVARY

  2016cites this paper
• Biomarkers towards Ovarian Cancer Diagnostics: Present and Future Prospects

  2016cites this paper
• The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study

  2016cites this paper
• Progress and prospects for the discovery of biomarkers for gastric cancer: a focus on proteomics

  2016cites this paper
• Proteomics and Human Diseases

  2016cites this paper
• Mesothelin as a biomarker for ovarian carcinoma: a meta-analysis.

  2016cites this paper
• Mesothelin versus Ca125 in Screening the Ovarian Malignancy

  2016cites this paper
• The construction of cDNA library and the screening of related antigen of ascitic tumor cells of ovarian cancer.

  2015cites this paper
• Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis

  2015cites this paper
• Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications.

  2015cites this paper
• JAJNIKA BIOCHEMICAL MARKERS IN BREAST AND OVARIAN CANCER

  2015cites this paper
• Proteomics analysis of bodily fluids in pancreatic cancer

  2015cites this paper
• Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset

  2015cites this paper
• Improved diagnosis of mesothelioma by a combination of soluble mesothelin-related peptide and CYFRA 21-1

  2015cites this paper
• Determination of the spectral dependence of reduced scattering and quantitative second-harmonic generation imaging for detection of fibrillary changes in ovarian cancer

  2015cites this paper
• Möglichkeiten und Grenzen der Diagnostik beim Ovarialkarzinom

  2014cites this paper
• Simultaneous electrochemical immunosensor based on water-soluble polythiophene derivative and functionalized magnetic material.

  2014cites this paper
• Evaluation of serum mesothelin in malignant and benign ovarian masses

  2014cites this paper
• Ovarian cancer biomarkers: current state and future implications from high-throughput technologies.

  2014cites this paper
• Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer

  2014cites this paper
• ASSOCIATION BETWEEN INTERLEUKIN 4 GENE SEVENTY-BASE-PAIR VARIABLE NUMBER OF TANDEM REPEATS POLYMORPHISM AND UTERINE LEIOMYOMA

  2014cites this paper
• Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients

  2014cites this paper
• Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4

  2013cites this paper
• Biomarkers for Early Detection of Ovarian Cancer

  2013cites this paper
• Early detection of ovarian cancer

  2013cites this paper
• Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.

  2013cites this paper
• TRANSGENIC MICROALGAE AS GREEN CELL FACTORIES

  2013cites this paper
• 2 Preventive Strategies in Epithelial Ovarian Cancer

  2012cites this paper
• Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

  2012cites this paper
• Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

  2012cites this paper
• Diagnostic value of HE4 for ovarian cancer: a meta-analysis

  2012cites this paper
• New Tumor Biomarkers in Ovarian Cancer and Its Prognostic and Clinical Relevance

  2012cites this paper
• HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection.

  2012cites this paper
• Potential Tumor Biomarkers for Ovarian Cancer

  2012cites this paper
• AUTOANTIBODIES TO MESOTHELIN IN INFERTILITY a,,b,,c

  2012cites this paper
• Oncology biomarkers for gynecologic malignancies.

  2012cites this paper
• Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.

  2012cites this paper
• Preventive Strategies in Epithelial Ovarian Cancer

  2012cites this paper
• Mesothelin expression correlates with prolonged patient survival in gastric cancer

  2012cites this paper
• Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer.

  2012cites this paper
• Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis.

  2012influential citation
• Etiology and overview

  2012cites this paper
• Early Detection Biomarkers for Ovarian Cancer

  2012cites this paper
• From the endometrium physiology to a comprehensive strategy for the discovery of ovarian cancer biomarkers

  2011cites this paper
• Status of tumor markers in epithelial ovarian cancer has there been any progress? A review.

  2011cites this paper
• Understanding the Cross-Talk between Ovarian Tumors and Immune Cells: Mechanisms for Effective Immunotherapies

  2011cites this paper
• Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer

  2011cites this paper
• Proteomics and biomarkers in clinical trials for drug development.

  2011cites this paper
• The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors

  2011cites this paper
• fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

  2011cites this paper
• Hereditary Ovarian Cancer and Other Gynecologic Malignancies

  2011cites this paper